Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003;23(4):235-43.
doi: 10.2165/00044011-200323040-00003.

Psychomotor and anxiolytic effects of mexazolam in patients with generalised anxiety disorder

Luís Ferreira  1 , Maria-Luísa Figueira, Alberto Bessa-Peixoto, António Marieiro, Rodolfo Albuquerque, Cristina Paz, Ana Cerqueira, Pedro Damião, Ana Dolgner, Jasper Dingemanse
Affiliations

Psychomotor and anxiolytic effects of mexazolam in patients with generalised anxiety disorder

Luís Ferreira et al. Clin Drug Investig. 2003.

Abstract

Objective: The primary aim of this study was to evaluate the psychomotor effects of mexazolam versus placebo in patients with generalised anxiety disorder (GAD).

Patients and methods: This was a multicentre, randomised, double-blind, parallel-group clinical trial in 60 outpatients with GAD (Diagnostic and Statistical Manual of Mental Disorders-4(th) edition [DSM-IV] criteria). After a placebo run-in period, patients were assigned to mexazolam 1mg three times daily (n = 32) or placebo (n = 28) for 21 days. Effects on psychomotor performance were evaluated with the Leeds Psychomotor Test Battery (critical flicker fusion threshold, recognition, motor and total reaction time). The Hamilton Anxiety Rating Scale (HAM-A) and the Clinical Global Impression (CGI) were used to evaluate the patients' clinical status (secondary objective).

Results: At neither assessment were any statistically significant differences detected between mexazolam and placebo for CGI, critical flicker fusion, and the different reaction times. The HAM-A total and the HAM-A somatic scores indicated a statistically significant therapeutic effect for mexazolam vs placebo after 1 week of treatment but not after 3 weeks. The most prominent adverse event with mexazolam was mild drowsiness.

Conclusions: Mexazolam in a therapeutically effective dosage regimen does not impair psychomotor performance to a clinically relevant extent.

PubMed Disclaimer

References

    1. J Clin Psychiatry. 2001;62 Suppl 8:4-9; discussion 10-1 - PubMed
    1. Curr Pharm Des. 2002;8(1):5-21 - PubMed
    1. J Clin Psychopharmacol. 1999 Apr;19(2):107-13 - PubMed
    1. J Clin Psychopharmacol. 2000 Jun;20(3):338-46 - PubMed
    1. Int Clin Psychopharmacol. 1994 Sep;9(3):145-53 - PubMed